Fishman, David

Publications

Sort by

Co-Author Network

selected publications

Survival After Minimally Invasive Surgery in Older Women With Endometrial Carcinoma. Anticancer research. 2022 Academic Article GET IT
Gynecologic oncology care during the COVID-19 pandemic at three affiliated New York City hospitals. Gynecologic oncology. 2020 Academic Article GET IT
Times cited: 30
NDN is an imprinted tumor suppressor gene that is downregulated in ovarian cancers through genetic and epigenetic mechanisms. Oncotarget. 2016 Academic Article GET IT
Times cited: 10
Endometriosis Presenting With Massive Ascites and an Elevated CA-125. Journal of minimally invasive gynecology. 2015 Academic Article GET IT
Expression of H1.5 and PLZF in granulosa cell tumors and normal ovarian tissues: a short report. Cellular oncology (Dordrecht). 2014 Academic Article GET IT
Times cited: 5
Comparison of robotic-assisted and conventional laparoscopy in the management of adnexal masses. Journal of minimally invasive gynecology. 2014 Academic Article GET IT
Times cited: 4
Immunohistochemical detection of promyelocytic leukemia zinc finger and histone 1.5 in uterine leiomyosarcoma and leiomyoma. Reproductive sciences (Thousand Oaks, Calif.). 2014 Academic Article GET IT
Times cited: 6
microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial-mesenchymal transition. Nature communications. 2014 Academic Article GET IT
Times cited: 223
Survival analysis of robotic versus traditional laparoscopic surgical staging for endometrial cancer. American journal of obstetrics and gynecology. 2013 Academic Article GET IT
Times cited: 44
Epithelial-mesenchymal transition enhances nanoscale actin filament dynamics of ovarian cancer cells. The journal of physical chemistry. B. 2013 Academic Article GET IT
Times cited: 17
Does the type of surgery for early-stage endometrial cancer affect the rate of reported lymphovascular space invasion in final pathology specimens?. American journal of obstetrics and gynecology. 2012 Academic Article GET IT
Times cited: 18
The NF-κB pathway mediates lysophosphatidic acid (LPA)-induced VEGF signaling and cell invasion in epithelial ovarian cancer (EOC). Gynecologic oncology. 2011 Academic Article GET IT
Times cited: 32
Recognition of linear stress fibers based on Hough transform. Analytical and quantitative cytology and histology. 2011 Academic Article GET IT
MMP-1-PAR1 axis mediates LPA-induced epithelial ovarian cancer (EOC) invasion. Gynecologic oncology. 2010 Academic Article GET IT
Times cited: 25
The dire need to develop a clinically validated screening method for the detection of early-stage ovarian cancer. Biomarkers in medicine. 2010 Editorial Article GET IT
Times cited: 8
Biomarkers for ovarian cancer detection and therapy. Cancer biology & therapy. 2010 Review GET IT
Times cited: 25
Advances in sonographic detection of ovarian cancer: depiction of tumor neovascularity with microbubbles. AJR. American journal of roentgenology. 2010 Review GET IT
Times cited: 46
Lysophosphatidic acid (LPA) effects on endometrial carcinoma in vitro proliferation, invasion, and matrix metalloproteinase activity. Gynecologic oncology. 2010 Academic Article GET IT
Times cited: 22
Chemotherapy for gynecologic cancers. The Mount Sinai journal of medicine, New York. 2009 Review GET IT
Times cited: 9
Roles of LPA in ovarian cancer development and progression. Future oncology (London, England). 2009 Information Resource GET IT
Times cited: 40
Diagnostic parameters to differentiate benign from malignant ovarian masses with contrast-enhanced transvaginal sonography. Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine. 2009 Academic Article GET IT
Times cited: 38
VEGFR-2 silencing by small interference RNA (siRNA) suppresses LPA-induced epithelial ovarian cancer (EOC) invasion. Gynecologic oncology. 2009 Academic Article GET IT
Times cited: 31
Biological significance of prolactin in gynecologic cancers. Cancer research. 2009 Academic Article GET IT
Times cited: 79
Lysophosphatidic acid and invasion. Cancer treatment and research. 2009 Review GET IT
Times cited: 4
Soluble epidermal growth factor receptor: a biomarker of epithelial ovarian cancer. Cancer treatment and research. 2009 Review GET IT
Times cited: 9
LPA receptor 2 mediates LPA-induced endometrial cancer invasion. Gynecologic oncology. 2008 Academic Article GET IT
Times cited: 38
The activity of medroxyprogesterone acetate, an androgenic ligand, in ovarian cancer cell invasion. Reproductive sciences (Thousand Oaks, Calif.). 2008 Academic Article GET IT
Times cited: 5
Contrast-enhanced transvaginal sonography of benign versus malignant ovarian masses: preliminary findings. Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine. 2008 Academic Article GET IT
Times cited: 56
Matrix metalloproteinase 9 is a mediator of epidermal growth factor-dependent e-cadherin loss in ovarian carcinoma cells. Cancer research. 2008 Academic Article GET IT
Times cited: 149
S1P induced changes in epithelial ovarian cancer proteolysis, invasion, and attachment are mediated by Gi and Rac. Gynecologic oncology. 2008 Academic Article GET IT
Times cited: 35
Overexpression of SnoN/SkiL, amplified at the 3q26.2 locus, in ovarian cancers: a role in ovarian pathogenesis. Molecular oncology. 2008 Academic Article GET IT
Times cited: 22
International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. International journal of cancer. 2008 Academic Article GET IT
Times cited: 299
Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation. Cancer. 2008 Academic Article GET IT
Times cited: 136
Lysophosphatidic acid (LPA) promotes E-cadherin ectodomain shedding and OVCA429 cell invasion in an uPA-dependent manner. Gynecologic oncology. 2008 Academic Article GET IT
Times cited: 30
Proteomic patterns for classification of ovarian cancer and CTCL serum samples utilizing peak pairs indicative of post-translational modifications. Proteomics. 2007 Academic Article GET IT
Times cited: 14
A robust biomarker discovery pipeline for high-performance mass spectrometry data. Journal of bioinformatics and computational biology. 2007 Academic Article GET IT
Times cited: 8
S1P and LPA have an attachment-dependent regulatory effect on invasion of epithelial ovarian cancer cells. Gynecologic oncology. 2007 Academic Article GET IT
Times cited: 34
A novel, high-throughput workflow for discovery and identification of serum carrier protein-bound peptide biomarker candidates in ovarian cancer samples. Clinical chemistry. 2007 Academic Article GET IT
Times cited: 103
Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer. Cancer research. 2007 Academic Article GET IT
Times cited: 101
Engagement of collagen-binding integrins promotes matrix metalloproteinase-9-dependent E-cadherin ectodomain shedding in ovarian carcinoma cells. Cancer research. 2007 Academic Article GET IT
Times cited: 180
Ovarian cancer classification based on mass spectrometry analysis of sera. Cancer informatics. 2007 Academic Article GET IT
Lysophosphatidic acid down-regulates stress fibers and up-regulates pro-matrix metalloproteinase-2 activation in ovarian cancer cells. Molecular cancer research : MCR. 2007 Academic Article GET IT
Times cited: 34
Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast cancer research and treatment. 2007 Academic Article GET IT
Times cited: 42
Conventional and proteomic technologies for the detection of early stage malignancies: markers for ovarian cancer. Critical reviews in clinical laboratory sciences. 2007 Review GET IT
Times cited: 14
Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. The Lancet. Oncology. 2007 Academic Article GET IT
Times cited: 203
Inhibition of matrilysin expression by antisense or RNA interference decreases lysophosphatidic acid-induced epithelial ovarian cancer invasion. Molecular cancer research : MCR. 2006 Academic Article GET IT
Times cited: 17
S1P regulation of ovarian carcinoma invasiveness. Gynecologic oncology. 2006 Academic Article GET IT
Times cited: 28
Progress in biomarker discovery for diagnostic testing in epithelial ovarian cancer. Expert review of molecular diagnostics. 2006 Review GET IT
Times cited: 10
Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers. Breast cancer research : BCR. 2006 Academic Article GET IT
Times cited: 43
Vascular endothelial growth factor-regulated ovarian cancer invasion and migration involves expression and activation of matrix metalloproteinases. International journal of cancer. 2006 Academic Article GET IT
Times cited: 66
Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays. Cancer research. 2006 Academic Article GET IT
Times cited: 197
The tumor microenvironment: key to early detection. Critical reviews in clinical laboratory sciences. 2006 Review GET IT
Times cited: 49
Selective induction of cyclooxygenase-2 plays a role in lysophosphatidic acid regulated Fas ligand cell surface presentation. FEBS letters. 2005 Academic Article GET IT
Times cited: 9
Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 Academic Article GET IT
Times cited: 240
Matrilysin over-expression in MCF-7 cells enhances cellular invasiveness and pro-gelatinase activation. Cancer letters. 2005 Academic Article GET IT
Times cited: 54
LPA-induced epithelial ovarian cancer (EOC) in vitro invasion and migration are mediated by VEGF receptor-2 (VEGF-R2). Gynecologic oncology. 2005 Academic Article GET IT
Times cited: 75
Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Review GET IT
Times cited: 149
Estradiol-induced ezrin overexpression in ovarian cancer: a new signaling domain for estrogen. Cancer letters. 2005 Academic Article GET IT
Times cited: 50
Matrilysin (MMP-7) promotes invasion of ovarian cancer cells by activation of progelatinase. International journal of cancer. 2005 Academic Article GET IT
Times cited: 145
Importance of communication between producers and consumers of publicly available experimental data. Journal of the National Cancer Institute. 2005 Academic Article GET IT
Times cited: 70
Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2005 Academic Article GET IT
Times cited: 51
Translocation of Fas by LPA prevents ovarian cancer cells from anti-Fas-induced apoptosis. Gynecologic oncology. 2005 Academic Article GET IT
Times cited: 25
Lysophosphatidic acid inhibits anti-Fas-mediated apoptosis enhanced by actin depolymerization in epithelial ovarian cancer. FEBS letters. 2005 Academic Article GET IT
Times cited: 12
Lysophosphatidic acid stimulates fas ligand microvesicle release from ovarian cancer cells. Cancer immunology, immunotherapy : CII. 2005 Academic Article GET IT
Times cited: 31
Telomerase prolongs the lifespan of normal human ovarian surface epithelial cells without inducing neoplastic phenotype. Journal of the Society for Gynecologic Investigation. 2004 Academic Article GET IT
Times cited: 19
Upregulation of FasL by LPA on ovarian cancer cell surface leads to apoptosis of activated lymphocytes. Gynecologic oncology. 2004 Academic Article GET IT
Times cited: 15
Lysophosphatidic acid enhances epithelial ovarian carcinoma invasion through the increased expression of interleukin-8. Gynecologic oncology. 2004 Academic Article GET IT
Times cited: 64
The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nature medicine. 2004 Academic Article GET IT
Times cited: 405
Proinvasive properties of ovarian cancer ascites-derived membrane vesicles. Cancer research. 2004 Academic Article GET IT
Times cited: 205
Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 Academic Article GET IT
Times cited: 369
A comparison of ovarian cancer treatments: analysis of utility assessments of ovarian cancer patients, at-risk population, general population, and physicians. Gynecologic oncology. 2004 Academic Article GET IT
Times cited: 17
Treatment of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine chemotherapy. Gynecologic oncology. 2003 Academic Article GET IT
Times cited: 79
Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2003 Academic Article GET IT
Times cited: 238
Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays. Proteomics. 2003 Academic Article GET IT
Times cited: 198
Genetic risk assessment for breast and ovarian cancer. Advance for nurse practitioners. 2003 Review GET IT
Comparison of statistical methods for classification of ovarian cancer using mass spectrometry data. Bioinformatics (Oxford, England). 2003 Academic Article GET IT
Times cited: 373
Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003 Academic Article GET IT
Times cited: 76
Reproductive factors and ovarian cancer risk in Jewish BRCA1 and BRCA2 mutation carriers (United States). Cancer causes & control : CCC. 2003 Academic Article GET IT
Times cited: 18
Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2003 Academic Article GET IT
Times cited: 87
Biomarker amplification by serum carrier protein binding. Disease markers. 2003 Academic Article GET IT
Times cited: 181
General keynote: proteomic patterns in sera serve as biomarkers of ovarian cancer. Gynecologic oncology. 2003 Review GET IT
Times cited: 28
Novel approaches to visualization and data mining reveals diagnostic information in the low amplitude region of serum mass spectra from ovarian cancer patients. Disease markers. 2003 Academic Article GET IT
Times cited: 13
Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women. Clinical cancer research : an official journal of the American Association for Cancer Research. 2002 Academic Article GET IT
Times cited: 112
Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins and promotes cell motility. Cancer research. 2002 Academic Article GET IT
Times cited: 467
Localization of the activin signal transduction components in normal human ovarian follicles: implications for autocrine and paracrine signaling in the ovary. The Journal of clinical endocrinology and metabolism. 2002 Academic Article GET IT
Times cited: 80
Interpreting three new and unique BRCA1 mutations in an Ashkenazi Jewish patient. Clinical genetics. 2002 Letter GET IT
Use of proteomic patterns in serum to identify ovarian cancer. Lancet (London, England). 2002 Academic Article GET IT
Times cited: 2801
Critical role of lysophospholipids in the pathophysiology, diagnosis, and management of ovarian cancer. Cancer treatment and research. 2002 Review GET IT
Times cited: 99
Early detection of ovarian cancer: promise and reality. Cancer treatment and research. 2002 Review GET IT
Times cited: 109
The scientific basis of early detection of epithelial ovarian cancer: the National Ovarian Cancer Early Detection Program (NOCEDP). Cancer treatment and research. 2002 Review GET IT
Times cited: 47
Ultrasound and ovarian cancer. Cancer treatment and research. 2002 Review GET IT
Times cited: 15
Three-dimensional power Doppler ultrasound improves the diagnostic accuracy for ovarian cancer prediction. Gynecologic oncology. 2001 Academic Article GET IT
Times cited: 177
Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet (London, England). 2001 Academic Article GET IT
Times cited: 196
Lysophosphatidic acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells. Cancer research. 2001 Academic Article GET IT
Times cited: 214
Evaluating the total costs of chemotherapy-induced toxicity: results from a pilot study with ovarian cancer patients. The oncologist. 2001 Academic Article GET IT
Times cited: 86
Whole-abdominal radiation in endometrial carcinoma: an analysis of toxicity, patterns of recurrence, and survival. Cancer journal (Sudbury, Mass.). 2000 Academic Article GET IT
Times cited: 19
Is transvaginal ultrasound effective for screening asymptomatic women for the detection of early-stage epithelial ovarian carcinoma?. Gynecologic oncology. 2000 Editorial Article GET IT
Times cited: 25
BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. American journal of human genetics. 2000 Academic Article GET IT
Times cited: 281
Autocrine regulation of growth stimulation in human epithelial ovarian carcinoma by serine-proteinase-catalysed release of the urinary-type-plasminogen-activator N-terminal fragment. The Biochemical journal. 1999 Academic Article GET IT
Times cited: 16
Ovarian carcinoma regulation of matrix metalloproteinase-2 and membrane type 1 matrix metalloproteinase through beta1 integrin. Cancer research. 1999 Academic Article GET IT
Times cited: 144
Perceptions of cisplatin-related toxicity among ovarian cancer patients and gynecologic oncologists. Gynecologic oncology. 1998 Academic Article GET IT
Times cited: 26
No association of the I1307K APC allele with ovarian cancer risk in Ashkenazi Jews. Cancer research. 1998 Academic Article GET IT
Times cited: 16
Management of twin pregnancies consisting of a complete hydatidiform mole and normal fetus. Obstetrics and gynecology. 1998 Academic Article GET IT
Times cited: 99
The role of proteolytic enzymes in the pathology of epithelial ovarian carcinoma. International journal of oncology. 1998 Review GET IT
Times cited: 86
Metastatic dissemination of human ovarian epithelial carcinoma is promoted by alpha2beta1-integrin-mediated interaction with type I collagen. Invasion & metastasis. 1998 Academic Article GET IT
Times cited: 75
Biochemical characterization of primary peritoneal carcinoma cell adhesion, migration, and proteinase activity. Gynecologic oncology. 1997 Academic Article GET IT
Times cited: 11
Production of extracellular matrix-degrading proteinases by primary cultures of human epithelial ovarian carcinoma cells. Cancer. 1997 Academic Article GET IT
Times cited: 90
Evidence for preferential adhesion of ovarian epithelial carcinoma cells to type I collagen mediated by the alpha2beta1 integrin. International journal of cancer. 1996 Academic Article GET IT
Times cited: 100
Radiation therapy as exclusive treatment for medically inoperable patients with stage I and II endometrioid carcinoma with endometrium. Gynecologic oncology. 1996 Academic Article GET IT
Times cited: 67
Membrane-type matrix metalloproteinase expression and matrix metalloproteinase-2 activation in primary human ovarian epithelial carcinoma cells. Invasion & metastasis. 1996 Academic Article GET IT
Times cited: 74
Extramammary Paget's disease of the vulva. Gynecologic oncology. 1995 Academic Article GET IT
Times cited: 79
Current approaches to diagnosis and treatment of ovarian germ cell malignancies. Current opinion in obstetrics & gynecology. 1994 Review GET IT
Times cited: 27

more ...

less ...

Background

education and training

B.A., Washington University 79
M.D., Texas Tech University, Health Sciences Center, School of Medicine 1988
M.S., University of Texas 1984

Contact

full name

David Fishman

primary email

daf2037@med.cornell.edu

webpage

Clinical Profile

VIVO Weill Cornell Medical College

David Fishman Professor of Clinical Obstetrics and Gynecology

Publications

selected publications

Background

education and training

Contact

full name

primary email

webpage

Phone

Publications

selected publications

Background

education and training

Contact

full name

primary email

webpage